Vogenx Inc.
VOGXHealthcare|Biotechnology|US
$17.45
-0.78 (-4.28%)
About
Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis. The company's lead product candidate is mizagliflozin, an orally administered, small molecule drug candidate being developed for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome.
Stock Price
+34.2%(1Y)
1M
-0.2%
3M
+34.2%
6M
+34.2%
YTD
+34.2%
1Y
+34.2%
3Y
+34.2%
5Y
+34.2%
Pipeline Summary
3 total trials0
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
Completed: 2Recruiting: 1
Active Trials (1)
Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia
NCT07760961Postbariatric Hypoglycemia
Phase 2Recruiting
Enrollment: 36 participants
Key Facts
Market Cap$259.2M
Employees4
CEOJames Green
IPO DateAug 12, 2026
Beta0.00
52-Week Range$12.95 – $38.41
Avg Volume155,746
ExchangeNASDAQ
Websitevogenx.com
Ownership
Float64.3%
Shares Outstanding14.9M
Recent Insider Trades
Wilkison WilliamAWARD
Oct 2, 2026155,000 shares @ $20.05
Toombs Kenneth JohnAWARD
Oct 2, 202650,000 shares @ $18.23
Pieraccini PeterAWARD
Oct 2, 202650,000 shares @ $18.23
Green JamesAWARD
Oct 2, 2026155,000 shares @ $20.05
DELMAR STEVEN RAWARD
Oct 2, 2026155,000 shares @ $18.23
Recent News
Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia
Oct 15, 2026 · accessnewswire.com
Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer
Oct 9, 2026 · accessnewswire.com
Vogenx Appoints Ken Toombs to Board of Directors
Sep 22, 2026 · accessnewswire.com
Jones Served as Sole Book-Running Manager for Vogenx's $81.3 Million Initial Public Offering
Aug 17, 2026 · prnewswire.com
Vogenx Announces Closing of Initial Public Offering
Aug 13, 2026 · accessnewswire.com
Data last updated: Nov 9, 2026, 04:39 AM